Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 study of PF-06842874 in healthy adults
NCT04124653Phase 1Completed
- Sponsor
- Pfizer
- Start
- Oct 2019
- Primary completion
- Jul 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of PF-06842874 in pulmonary arterial hypertension (PAH) (2 arms), sponsored by Pfizer. Primary endpoints: Number of Participants With Treatment Emergent Treatment-Related Adverse Events, Number of Participants With Clinical Laboratory Abnormalities and 3 more. Started Oct 2019; status: completed.
02
Drugs
PF-06842874
03
Conditions
pulmonary arterial hypertension (PAH)
Beyond the preview
Go deeper on NCT04124653.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04124653.